Formycon's 2025 Financial Results and Strategic Outlook for 2026

Formycon AG reported a successful financial year for 2025, marked by significant operational progress, despite lower-than-forecasted revenue. The company achieved important milestones across its biosimilar pipeline and witnessed a strengthened financial position, notably aided by a €70 million corporate bond placement. Group revenue stood at €44.5 million, falling short of the anticipated €55.0 million to €65.0 million range due to delayed partnerships and deferred milestone payments. However, the Group's EBITDA of €-3.6 million and adjusted EBITDA of €-2.3 million surpassed initial expectations.

Strategic highlights for Formycon include the advancement of its FYB4Growth strategy, focusing on sustainable, scalable, and value-creating growth. The strategy underpins Formycon’s robust development and strategic partnerships with a focus on geographic expansion and a diversified biosimilar portfolio targeting key markets like MENA, APAC, and Latin America.

Looking ahead to 2026, Formycon anticipates revenue growth to €60.0 million to €70.0 million, with a projected positive EBITDA. Key activities include the U.S. reintroduction of FYB201/Cimerli® and the expanded commercialization of FYB202 and FYB203.